AgeneBio's HOPE4MCI Phase 3 trial receives support from NIH

AgeneBio, a biopharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, announced today that its HOPE4MCI Phase 3 clinical trial has received support from the National Institutes of Health (NIH). The five-year, estimated $7.5 million grant initiates a public-private partnership among the NIH's National Institute on Aging, Johns Hopkins University, and AgeneBio to study AGB101 and its potential to prevent or delay the onset of Alzheimer's dementia. The HOPE4MCI Phase 3 trial is the first and only trial to reduce hippocampal overactivity during amnestic mild cognitive impairment (aMCI), the symptomatic pre-dementia stage of Alzheimer's, and is expected to begin in early 2016.

AGB101 and the HOPE4MCI Phase 3 Trial
AGB101 is a proprietary once-a-day low-dose formulation of levetiracetam, an anti-epileptic treatment commercialized for more than a decade with a well-characterized safety profile at daily doses greater than twelve times the intended dose for AGB101. Phase 2 clinical results showed that AGB101 restored brain network function and significantly improved memory in elderly patients with aMCI. AgeneBio expects to initiate the HOPE4MCI Phase 3 trial in early 2016 utilizing a primary endpoint that is aligned with recent US Food and Drug Administration (FDA) guidance for aMCI trials. If approved, AGB101 would be the first and only therapeutic that reduces hippocampus overactivity and potentially the first therapeutic to prevent or delay the onset of Alzheimer's dementia. Co-principal investigators on the NIH grant are Michela Gallagher, PhD, Krieger-Eisenhower Professor of Psychological and Brain Sciences and Director of the Neurogenetics and Behavior Center at Johns Hopkins University and AgeneBio founder, and Marilyn Albert, PhD, Professor of Neurology and Director of the Division of Cognitive Neuroscience in the Department of Neurology at Johns Hopkins University School of Medicine and Director of the Johns Hopkins Alzheimer's Disease Research Center (JHADRC).

Dr. Gallagher noted, "The state of the science points to hippocampal overactivity in aMCI as a strong predictor of progression to Alzheimer's dementia and the earliest point at which this pre-dementia condition can be diagnosed before significant irreversible neurodegeneration kills brain cells. We expect our upcoming trial to demonstrate efficacy in preserving cognition and memory in aMCI patients while delaying progression to the clinical stage of Alzheimer's dementia."

"We believe our novel approach to delaying the onset of Alzheimer's dementia by targeting aMCI offers promising hope to solving this medical crisis facing millions of patients and their families," said AgeneBio President and CEO Jerry McLaughlin. "HOPE4MCI is now among an elite group of Alzheimer's prevention public-private partnership trials funded by the NIH, which is committed to advancing clinical programs targeting this devastating disease. If approved, we believe this groundbreaking therapy offers both a significant commercial opportunity and enormous social value with a substantial positive public health impact."

NIH-Funded Alzheimer's Prevention Public-Private Partnerships
The HOPE4MCI trial grant is part of the NIH's National Institute on Aging National Plan to Address Alzheimer's Disease, which is charged with preventing or effectively treating Alzheimer's disease by 2025. Through its public-private partnership grants, NIH hopes to find solutions and treatments for some of the greatest health challenges facing Americans by bringing together private business ventures, academic institutions and government entities. NIH conducts rigorous scientific peer reviews to vet potential trials for its public-private partnership grants. In addition to the HOPE4MCI trial, other NIH-funded public-private partnerships for the prevention of Alzheimer's disease include the Alzheimer's Prevention Initiative Trials (Banner Alzheimer's Institute and Genentech), the A4 Trial (between the Alzheimer's Disease Cooperative Study and Eli Lilly) and the ApoE4 Prevention Trial (Banner Alzheimer's Institute and Novartis).


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
AI model revolutionizes dementia diagnosis with high accuracy across multiple data sources